An observational study in Angioedema, sponsored by University Hospital, Grenoble. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-29.
Sponsored by University Hospital, Grenoble · Observational
Diagnosis of angioedema (AE) is difficult especially in emergency room. Two forms should be evoked: histaminic AE (allergic or not, which represent 95% of cases) and bradykinic AE (hereditary or acquired deficiency, with or without C1 Inhibitor) rarer but with more severe prognosis. The distinction is based on clinical features (spontaneous crisis duration, presence of concomitant hives, atopic history...). Sometimes it could be difficult to make the difference. Nowadays, there is no biological marker of the crisis. The search for biomarkers could improve the diagnostic and therapeutic management of AE. Previous work has identified targets: D-dimer, C4, and VE-cadherin. We wanted to know the sensitivity and specificity of these markers.
We conducted a prospective study evaluating the D-dimer assays, complement and VE-cadherin during an episode of AE. Three groups of patients were tested: bradykinic AE (peripheral or abdominal attacks), histaminic AE, and abdominal pain (non-bradykinic and non-histaminic etiology) at the time (day 0) and at distance from the crisis (D7).
164 studies on the registry are indexed under Angioedema; 19 are open to participants now.
This study's enrollment of 120 is below the median of 163 across 44 observational studies indexed under Angioedema.
Browse Angioedema studies →University Hospital, Grenoble is the lead sponsor of 815 studies on the registry; 205 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with bradykinin and histaminergic angioedema or with abdominal pain
Exclusion Criteria:
Hereditary angioedema with or without C1Inhibitor Drug induced angiodema
Allergic and non allergic angioedema
Patients with abdominal pain
VE CADHERIN SENSITIVITY AND SPECIFICITY
Time frame: 7 DAYS
D-DIMERS SENSITIVITY AND SPECIFICITY
Time frame: 7 DAYS
C1INHIBITOR
Time frame: 7 DAYS
Plan to share: Undecided
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Grenoble